Effect of an ATP-Sensitive Potassium Channel Opener in Subjects with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled Study (ZD0947IL/0004)

European Urology

Volumn 49, Issue 5, 2006, Pages 879-886

  Chapple, Christopher R ^a   Patroneva, Albena ^b   Raines, Shane R ^b  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Potassium channels; Randomized controlled trial; Urinary incontinence

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG; ZD 0947;

ADULT; AGED; ARTHRALGIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; ECG ABNORMALITY; FEMALE; HEART RATE VARIABILITY; HUMAN; INCONTINENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORTHOSTATIC HYPOTENSION; OUTCOMES RESEARCH; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE BLIND PROCEDURE; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; URINARY FREQUENCY; URINE VOLUME; VASODILATATION;

ADOLESCENT; ADULT; AGED; DIHYDROPYRIDINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POTASSIUM CHANNELS, INWARDLY RECTIFYING; QUALITY OF LIFE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY INCONTINENCE; URODYNAMICS;

EID: 33645779772     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.01.037     Document Type: Article

References (20)

1. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 (2002) 167-178
2. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 62 (2003) 28-37
3. Andersson K.-E. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology 63 (2004) 32-41
4. Herbison P., Hay-Smith J., Ellis G., and Moore K. Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 326 (2003) 841-844
5. Scheife R., and Takeda M. Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27 (2005) 144-153
6. Chapple C.R. Darifenac: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 13 (2004) 1493-1500
7. Cardozo L., Lisec M., Millard R., Van Vierssen T.O., Kuzmin I., Drogendijk T.E., et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172 (2004) 1919-1924
8. Zinner N., Gittelman M., Harris R., Susset J., Kanellos A., Auerbach S., and for the Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171 (2004) 2311-2315
9. Kumar V., Templeman L., Chapple C.R., and Chess-Williams R. Recent developments in the management of detrusor overactivity. Curr Opin Urol 13 (2003) 285-291
10. Avery K., Donovan J., and Abrams P. Validation of a new questionnaire for incontinence: The International Consultation on Incontinence Questionnaire (ICIQ). Neurourol Urodynam 20 (2001) 510
11. Donovan J, Bosch R, Goto HM, Jackson S Norton, Radley S, Valiquette L. Chapter 10, Incontinence, vol. 1. Basics and evaluation. In: Abrams P, Cardozo L, Khoury S, Wein A, editors. Symptom & quality of life assessment. Health & Publication Ltd., 2005, pp. 519-584, ISBN 0-9546958-2-3.
12. Kelleher C.J., Cardozo L.D., Khullar V., and Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynecol 104 (1997) 1374-1379
13. Van Kerrebroeck P., Kreder K., Jonas U., Zinner N., Wein A., and on behalf of the Tolterodine Study Group. Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder. Urology 57 (2001) 414-421
14. Larsson G., Hallén B., and Nilvebrant L. Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 53 (1999) 990-998
15. Drutz H.P., Appell R.A., Gleason D., Klimberg I., and Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 10 (1999) 283-289
16. Abdel-Karim A.M., Bialecki R.A., and Elhilali M.M. Effects of ZD6169 and ZD0947, 2 potassium adenosine triphosphate channel openers, on bladder function of spinalized rats. J Urol 168 (2002) 837-842
17. Moussa S, Kashiwabara T, Bialecki R, Elhilali M. Comparative study of the effects of ZD0947 and tolterodine on bladder function in a paraplegic rat model. Abstract (#221) presented at the annual meeting of the International Continence Society, Paris, 23-27 August, 2004.
18. Papazian D.M., Schwartz T.L., Tempel B.L., Jan Y.N., and Jan L.Y. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. Science 237 (1987) 749-753
19. Gopalakrishnan M., and Shieh C.-C. Potassium channel subtypes as molecular targets for overactive bladder and other urological disorders. Expert Opin Ther Targets 8 (2004) 437-458
20. Fryer R.M., Preusser L.C., Calzadilla S.V., Hu Y., Xu H., Marsh K.C., et al. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637), a novel ATP-sensitive potassium channel opener: hemodynamic comparison to ZD-6169, WAY-133537, and nifedipine in the anesthetized canine. J Cardiovasc Pharmacol 44 (2004) 137-147